NASDAQ · LTRN
Healthcare · Biotechnology
$0.59
Down-$0.02 (-2.61%)
Updated Nov 5, 2026, 5:35 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LTRN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
LTRN closed at $0.59 after 21 trading sessions, down 35.54% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $0.64 | $0.64 | $0.5651 | $0.5866 | 88.27K |
| Nov 3, 2026 | $0.6683 | $0.677 | $0.5806 | $0.6023 | 187.28K |
| Nov 2, 2026 | $0.70 | $0.7378 | $0.635 | $0.64 | 176.07K |
| Oct 30, 2026 | $0.722 | $0.7409 | $0.635 | $0.6608 | 218.53K |
| Oct 29, 2026 | $0.77 | $0.84 | $0.73 | $0.731 | 233.91K |
| Oct 28, 2026 | $0.656 | $0.816 | $0.6401 | $0.7737 | 603.76K |
| Oct 27, 2026 | $0.61 | $0.6501 | $0.60 | $0.64 | 72.39K |
| Oct 26, 2026 | $0.63 | $0.6599 | $0.6006 | $0.6238 | 116.13K |
| Oct 23, 2026 | $0.65 | $0.66 | $0.591 | $0.6354 | 196.57K |
| Oct 22, 2026 | $0.6788 | $0.7093 | $0.6407 | $0.6407 | 109.51K |
| Oct 21, 2026 | $0.667 | $0.7112 | $0.667 | $0.6845 | 115.72K |
| Oct 20, 2026 | $0.626 | $0.7501 | $0.5982 | $0.6564 | 1.88M |
| Oct 19, 2026 | $0.6521 | $0.7151 | $0.64 | $0.6413 | 105.81K |
| Oct 16, 2026 | $0.684 | $0.7349 | $0.625 | $0.6684 | 258.56K |
| Oct 15, 2026 | $0.66 | $0.7055 | $0.6551 | $0.6668 | 234.27K |
| Oct 14, 2026 | $0.71 | $0.7106 | $0.651 | $0.673 | 212.26K |
| Oct 13, 2026 | $0.7237 | $0.80 | $0.70 | $0.7107 | 162.54K |
| Oct 12, 2026 | $0.849 | $0.85 | $0.7201 | $0.737 | 184.05K |
| Oct 9, 2026 | $0.83 | $0.8301 | $0.7603 | $0.8127 | 274.88K |
| Oct 8, 2026 | $0.8885 | $0.90 | $0.83 | $0.83 | 250.75K |
| Oct 7, 2026 | $0.9538 | $0.9999 | $0.89 | $0.91 | 224.08K |
The latest Smart Investors Daily articles mentioning LTRN.
Company
Market Activity
Research & News
LTRN research
Company profile and research snapshot.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 2, 2025 | Lake Street | Buy | — |
| Apr 25, 2024 | HC Wainwright & Co. | Neutral | — |
| Aug 10, 2023 | EF Hutton | Buy | — |
| Jun 26, 2023 | EF Hutton | Buy | — |
| May 18, 2023 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
Benzinga · Jul 23, 2026
The United States Patent and Trademark Office has issued Lantern Biopharma a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled "Methods for the Treatment of Solid Tumor Cancers Using Illudins
businesswire.com · Dec 3, 2025
DALLAS--(BUSINESS WIRE)--LP-184 Clinical Insights, KOL Webinar & Future Plans.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LTRN.
